Alector (ALEC) has an average rating of outperform and price targets ranging from $6 to $54, according to analysts polled by Capital IQ. (MT Newswires...
Alector (ALEC) said AbbVie (ABBV) subsidiary AbbVie Biotechnology ended one of the two programs in their 2017 Alzheimer's disease collaboration, according...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
| Address | 131 Oyster Point Boulevard South San Francisco, California 94080-2029 |
| Phone | +1.415.231.5660 |
| Number of Employees | N/A |
| Recent SEC Filing | 08/04/2022 8-K |
| Chief Executive Officer & Director | Arnon Rosenthal |
| President, Head-Research & Development | Saraswati Kenkare-Mitra |
| Chief Financial, Accounting & Business Officer | Marc Edward Grasso |
| VP-Technology & Digital Health | Charles Wolfus |
| Price Open | $13.17 |
| Previous Close | $13.06 |
| 52 Week Range | $7.50 - 29.30 |
| Market Capitalization | $1.1 B |
| Shares Outstanding | 83.3 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 11/03/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | 33.49 |
| Earnings per Share | $0.38 |
| Beta vs. S&P 500 | N/A |
| Revenue | $27.7 M |
| Net Profit Margin | 12.06% |
| Return on Equity | 12.16% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
